NANOBIOTIX (NANO.PA) Stock Price, Forecast & Analysis
Europe - EPA:NANO - FR0011341205 - Common Stock
NANO.PA Key Statistics, Chart & Performance
The current stock price of NANO.PA is 18.2 EUR. In the past month the price increased by 11.66%. In the past year, price increased by 414.29%.
NANO.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 74.11 | 49.28B | ||
| 1AE.DE | ARGENX SE | 74.35 | 49.44B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.32B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.41B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.99B | ||
| GLPG.AS | GALAPAGOS NV | 23.7 | 1.75B | ||
| 5CV.DE | CUREVAC NV | 5.19 | 1.02B | ||
| PHIL.MI | PHILOGEN SPA | 20.79 | 692.99M | ||
| IVA.PA | INVENTIVA SA | N/A | 505.40M | ||
| ALCLS.PA | CELLECTIS | N/A | 411.83M | ||
| FYB.DE | FORMYCON AG | N/A | 410.83M | ||
| VLA.PA | VALNEVA SE | N/A | 323.74M |
Related stock screener links
About NANO.PA
Company Profile
Nanobiotix SA is a late-stage biotechnology company, which engages in the development of therapeutic approaches to the treatment of cancer. The company is headquartered in Paris, Ile-De-France and currently employs 103 full-time employees. The company went IPO on 2012-10-29. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The company develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
Company Info
NANOBIOTIX
60 rue de Wattignies
Paris ILE-DE-FRANCE FR
Employees: 108
Phone: 33140260470
NANOBIOTIX / NANO.PA FAQ
What does NANO do?
Nanobiotix SA is a late-stage biotechnology company, which engages in the development of therapeutic approaches to the treatment of cancer. The company is headquartered in Paris, Ile-De-France and currently employs 103 full-time employees. The company went IPO on 2012-10-29. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The company develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
Can you provide the latest stock price for NANOBIOTIX?
The current stock price of NANO.PA is 18.2 EUR. The price decreased by -0.22% in the last trading session.
Does NANO stock pay dividends?
NANO.PA does not pay a dividend.
How is the ChartMill rating for NANOBIOTIX?
NANO.PA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the GICS sector and industry of NANO stock?
NANOBIOTIX (NANO.PA) operates in the Health Care sector and the Biotechnology industry.
Can you provide the upcoming earnings date for NANOBIOTIX?
NANOBIOTIX (NANO.PA) will report earnings on 2026-03-31, after the market close.
Who owns NANOBIOTIX?
You can find the ownership structure of NANOBIOTIX (NANO.PA) on the Ownership tab.
NANO.PA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to NANO.PA. When comparing the yearly performance of all stocks, NANO.PA is one of the better performing stocks in the market, outperforming 99.55% of all stocks.
NANO.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to NANO.PA. NANO.PA may be in some trouble as it scores bad on both profitability and health.
NANO.PA Financial Highlights
Over the last trailing twelve months NANO.PA reported a non-GAAP Earnings per Share(EPS) of -1.09. The EPS decreased by -47.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -114.32% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NANO.PA Forecast & Estimates
12 analysts have analysed NANO.PA and the average price target is 19.4 EUR. This implies a price increase of 6.58% is expected in the next year compared to the current price of 18.2.
For the next year, analysts expect an EPS growth of 55.38% and a revenue growth 53.48% for NANO.PA